Healthcare Royalty, Inc. (HCRX)

Healthcare Royalty was planning to go public, but the IPO has been withdrawn.
Stock Price: $15.00 - $17.00
Current IPO price range
Chart not available yet
Data will show when the stock starts trading.
Market Cap 3.45B
Revenue (ttm) 263.48M
Net Income (ttm) 107.63M
Shares Out 215.50M
EPS (ttm) 0.50
PE Ratio 32.04
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About HCRX

Healthcare Royalty is the leading mid-market royalty acquisition company, based upon the number of transactions and aggregate value of capital deployed since 2016. We focus on growth assets and emerging companies driving innovation in the biopharmaceutical industry. Our mission is to facilitate innovation by deploying capital consistently and reliably in products that serve unmet or underserved medical needs. We intend to achieve this mission by expanding our portfolio of approved and pre-approval products using cash flow generated by our exist... [Read more...]

Industry Biotechnology
Founded 2006
CEO Clarke B. Futch
Employees 25
Stock Exchange NASDAQ
Ticker Symbol HCRX
Full Company Profile

Financial Performance

In 2020, HCRX's revenue was $228.83 million, an increase of 29.06% compared to the previous year's $177.31 million. Earnings were $253.25 million, an increase of 46.77%.

Financial Statements


Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners

Spero Therapeutics Inc (NASDAQ: SPRO) has entered into a revenue interest financing agreement with HealthCare Royalty Partners for up to $125 million.  Spero will use the proceeds to prepare for the ant...

Other symbols: SPRO